Upstate Active Clinical Trials

Study Title:

I-501719 - A Phase II Study of CPX-351 in Younger Patients (< 60 Years Old) with Secondary Acute Myeloid Leukemia

What is the purpose of the study? (in Layman's terms, please describe the study)

This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine (CPX-351) works in treating patients with secondary acute myeloid leukemia who are younger than 60 years old. Drugs used in chemotherapy, such as CPX-351, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Upstate Institutional Review Board (IRB) Number:

2127457

Study/Protocol ID:

I-501719

Study Phase:

II

Patient Age Group:

Adults

Principal Investigator:

Krishna B Ghimire, MD

What is involved if I participate?

• How long is the study?
  > 6 years
• Is transportation provided or reimbursed?
  No
• Is parking provided or reimbursed?
  No
• What tests and procedures are involved?
  Bone marrow biopsy/aspirates, EKGs, Chest XR or CT, ECHOs. Please contact the CRA for more information.

Where will the study take place?

SUNY Upstate Medical University

Other Information:

N/A

ClinicalTrials.Gov ID:

NCT04269213

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Kelsey F Christo, MS BS
Phone: 315-464-5751
Email: [email protected]

Return to Previous Page || Search Again